News | February 09, 2015

Testing and Treating PAD Patients Prevents Loss of Legs, Feet

ISET 2015 discussed treatment options for critical limb ischemia

peripheral arterial disease, Atherectomy devices, ISET

Image courtesy of Vital Images

February 9, 2015 — Ensuring that patients with peripheral arterial disease (PAD) get tested and treated with minimally invasive endovascular therapy saves legs and lives suggests a study in which amputation rates fell by nearly 80 percent after such a system was implemented. The research was presented at the 27th annual International Symposium on Endovascular Therapy (ISET).

About 150,000 Americans undergo leg or foot amputations every year mostly due to poor circulation caused by PAD. Eight to 12 million Americans – one in 20 who are 50 or older – have PAD, in which plaque builds up in blood vessels in the legs, decreasing blood flow. Because amputation has such a negative impact on quality of life, half of people who have the procedure die within 18 months.

“Most PAD patients don’t undergo testing to analyze blood flow first, they just have a leg or foot amputated,” said Julio Sanguily III, M.D., lead author of the study and vascular surgeon with Martin Health System, Stuart, Florida. “In recent years there has been a revolution in endovascular therapy and we’re able to treat calcified and smaller vessels, meaning we can significantly improve blood flow and save limbs that once weren’t considered salvageable. And that saves lives.”

He said the key is twofold: to educate physicians who treat elderly patients and those with diabetes or kidney failure – who are at highest risk for these problems – regarding the improved options and provide them the ability to refer patients to a limb salvage program that features a multidisciplinary team, including endovascular therapy specialists, podiatrists and other support staff.

The number of amputations at Martin Health System fell by 79 percent over five years after the center implemented a limb salvage program, ensuring patients with PAD have an angiogram – an X-ray of the blood vessels to assess blood flow. Significantly more people were evaluated as well, due to a program to increase awareness about PAD among patients and educate physicians regarding the options for their patients with PAD.

Whenever possible, the patients then received treatment to open up the blood flow in the legs, including angioplasty, other minimally invasive treatments such as atherectomy and hyperbaric oxygen therapy. Hardened or calcified plaque is the most challenging problem and atherectomy – a roto-rooter type device that removes plaque – has proved particularly helpful in treating patients with this problem, Sanguily said.

Each year significantly more Martin Health System patients were evaluated, yet the number who had amputations plummeted. In 2010, 24 of the 84 patients (29 percent) who were evaluated had amputations; in 2011, 146 were evaluated and 18 (12 percent) had amputations; in 2012, 228 were evaluated and 10 had amputations (4 percent); in 2013, 249 were evaluated and 6 had amputations (2 percent) and in 2014, 500 were evaluated and five had amputations (1 percent).

For more information: www.iset.org

 

Related Content

Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI).

The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI). This image shows how the covered stents used with the system connect to create a new arterial pathway.

News | Peripheral Artery Disease (PAD)| August 02, 2017
Aug.
Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons| July 26, 2017
The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the...
Overlay Init